Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Endocrine 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Colorectal Neoplasms 8Lung Neoplasms 7Neoplasms 6Melanoma 5Thyroid Neoplasms 3Pancreatic Neoplasms 3Glioma 3Adenocarcinoma of Lung 3Rectal Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Hematologic Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sexual Dysfunction, Physiological 1Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer 1Prostatic Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1

Interventions

pembrolizumab 6Nivolumab 3Gemcitabine 3Cisplatin 3Carboplatin 3brigimadlin 2Ramucirumab 2Fluorouracil 2Docetaxel 2Cetuximab 2tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1regorafenib 1pertuzumab 1milademetan 1larotrectinib 1futibatinib 1durvalumab 1cemiplimab 1adagrasib 1Trastuzumab 1TAS-116 1Ritonavir 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Omacor 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × trametinib × Thoracic × Clear all
NCT01324258 2017-11-13

Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors

GlaxoSmithKline

Phase 1 Completed
19 enrolled
GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡